AG真人官方

CAESAREA, Israel, Aug. 6, 2025 /PRNewswire/ -- (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced 聽it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2025 before the Nasdaq Stock Market opens on Wednesday, August 13, 2025. The Company will also discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT on the same day.

Conference call & webcast info:
Wednesday, August 13, 2025, at 11:00 am EDT
US: 1-888-407-2553
Israel/International: +972-3-918-0696
A live webcast will be available at:
A recording of the webcast will be available at:

About IceCure Medical
IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense庐 system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example,聽IceCure聽is using forward looking statements in this press release when it discusses: its expected announcement of financial and operational results as of and for the six months ended June 30, 2025 and hosting a conference call related to such results聽. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in聽the United States聽and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the聽Middle East, specifically in聽Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended聽December 31, 2024聽filed with the SEC on聽March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website,聽. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

IR Contact:

Email: [email protected]

Michael Polyviou

Phone: 732-232-6914

Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg

View original content:

SOURCE IceCure Medical